Multiple therapies relieve long-term tardive dyskinesia in a patient with chronic schizophrenia: A case report.
Abstract
[BACKGROUND] Tardive dyskinesia (TD) is a serious and disabling movement disorder; it impairs social function and quality of life and increases the mortality rate. TD is usually induced by the use of antipsychotic drugs; however, the underlying mechanism remains unclear. Pharmacotherapy of TD includes cholinergic drugs, benzodiazepines, ginkgo biloba extract (GBE), antioxidants, amantadine, propanolol, botulinum toxin, valbenazine, and deutetrabenazine, whereas the non-pharmacotherapy approach includes modified electroconvulsive therapy (MECT) and deep brain stimulation. We successfully treated a chronic schizophrenia patient with comorbid long-term severe TD using deutetrabenazine, clozapine, and MECT.
[CASE SUMMARY] A 69-year-old woman who was diagnosed as having schizophrenia 16 years ago developed severe TD after 6-mo prescription of risperidone oral solution. Her TD symptoms did not resolve despite various treatments, such as GBE, vitamin E, trihexyphenidyl, promethazine, benzodiazepines, and switching to quetiapine and olanzapine. After admission, she was given deutetrabenazine 6 mg bid. Her buccal tremor was slightly resolved 3 d later; however, her tongue remained protruded and could not be retracted. Quetiapine was switched to clozapine on day 4, and the buccal tremor remarkably resolved, and the tongue could be retracted into the mouth from day 6 onward. After three sessions of MECT, the buccal tremor resolved further. Since then, she has been able to take a semifluid diet, and her quality of life improved remarkably during 6 mo of follow-up.
[CONCLUSION] TD is a serious condition which could be caused by antipsychotic medications; however, the best strategy against TD is prevention and monitoring during using antipsychotics. For patients with TD caused by antipsychotic medication use, multiple measures should be considered like switching to clozapine, adjunction with deutetrabenazine, or even MECT.
[CASE SUMMARY] A 69-year-old woman who was diagnosed as having schizophrenia 16 years ago developed severe TD after 6-mo prescription of risperidone oral solution. Her TD symptoms did not resolve despite various treatments, such as GBE, vitamin E, trihexyphenidyl, promethazine, benzodiazepines, and switching to quetiapine and olanzapine. After admission, she was given deutetrabenazine 6 mg bid. Her buccal tremor was slightly resolved 3 d later; however, her tongue remained protruded and could not be retracted. Quetiapine was switched to clozapine on day 4, and the buccal tremor remarkably resolved, and the tongue could be retracted into the mouth from day 6 onward. After three sessions of MECT, the buccal tremor resolved further. Since then, she has been able to take a semifluid diet, and her quality of life improved remarkably during 6 mo of follow-up.
[CONCLUSION] TD is a serious condition which could be caused by antipsychotic medications; however, the best strategy against TD is prevention and monitoring during using antipsychotics. For patients with TD caused by antipsychotic medication use, multiple measures should be considered like switching to clozapine, adjunction with deutetrabenazine, or even MECT.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | brain
|
scispacy | 1 | ||
| 해부 | oral
|
scispacy | 1 | ||
| 해부 | tongue
|
scispacy | 1 | ||
| 합병증 | buccal tremor
|
scispacy | 1 | ||
| 합병증 | buccal
|
scispacy | 1 | ||
| 합병증 | mouth
|
scispacy | 1 | ||
| 약물 | benzodiazepines
|
C0005064
Benzodiazepines
|
scispacy | 1 | |
| 약물 | ginkgo biloba extract
|
C0772125
Ginkgo biloba extract
|
scispacy | 1 | |
| 약물 | GBE
→ ginkgo biloba extract
|
C0772125
Ginkgo biloba extract
|
scispacy | 1 | |
| 약물 | amantadine
|
C0002403
amantadine
|
scispacy | 1 | |
| 약물 | propanolol
|
C0033497
propranolol
|
scispacy | 1 | |
| 약물 | valbenazine
|
C4078701
valbenazine
|
scispacy | 1 | |
| 약물 | clozapine
|
C0009079
clozapine
|
scispacy | 1 | |
| 약물 | risperidone
|
C0073393
risperidone
|
scispacy | 1 | |
| 약물 | vitamin E
|
C0042874
vitamin E
|
scispacy | 1 | |
| 약물 | trihexyphenidyl
|
C0041009
trihexyphenidyl
|
scispacy | 1 | |
| 약물 | promethazine
|
C0033405
promethazine
|
scispacy | 1 | |
| 약물 | quetiapine
|
C0123091
quetiapine
|
scispacy | 1 | |
| 약물 | olanzapine
|
C0171023
olanzapine
|
scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | botulinum
|
scispacy | 1 | ||
| 약물 | deutetrabenazine
|
scispacy | 1 | ||
| 약물 | [CONCLUSION] TD
|
scispacy | 1 | ||
| 질환 | tardive dyskinesia
|
C0686347
Tardive Dyskinesia
|
scispacy | 1 | |
| 질환 | schizophrenia
|
C0036341
Schizophrenia
|
scispacy | 1 | |
| 질환 | movement disorder
|
C0026650
Movement Disorders
|
scispacy | 1 | |
| 질환 | comorbid long-term severe TD
|
scispacy | 1 | ||
| 질환 | tremor
|
C0040822
Tremor
|
scispacy | 1 | |
| 기타 | patient
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.